Recombinant Human u-Plasminogen Activator/Urokinase, CF
Recombinant Human u-Plasminogen Activator/Urokinase, CF Summary
Product Specifications
Met1-Leu431 with a C-terminal 10-His tag
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
1310-SE
Formulation | Supplied as a 0.2 μm filtered solution in HEPES, NaCl and CaCl2. |
Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Assay Procedure
- Assay Buffer: 50 mM Tris, 0.01% (v/v) Tween® 20, pH 8.5
- Recombinant Human u‑Plasminogen Activator (uPA)/Urokinase (rhuPA) (Catalog # 1310-SE)
- Substrate: Z-Gly-Gly-Arg-AMC (Bachem, Catalog # I-1140), 10 mM stock in DMSO
- F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
- Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent
- Dilute rhuPA to 1 ng/µL in Assay Buffer.
- Dilute Substrate to 200 µM in Assay Buffer.
- Load 50 µL of the 1 ng/µL rhuPA into a black well plate, and start the reaction by adding 50 µL of 200 µM Substrate. Include a Substrate Blank containing 50 µL Assay Buffer and 50 µL of 200 µM Substrate without any rhuPA.
- Read at excitation and emission wavelengths of 380 nm and 460 nm (top read), respectively, in kinetic mode for 5 minutes.
- Calculate specific activity:
Specific Activity (pmol/min/µg) = |
Adjusted Vmax* (RFU/min) x Conversion Factor** (pmol/RFU) |
amount of enzyme (µg) |
*Adjusted for Substrate Blank
**Derived using calibration standard 7-amino, 4-Methyl Coumarin (Sigma, Catalog # A-9891)
- rhuPA: 0.05 µg
- Substrate: 100 µM
Scientific Data
Recombinant Human u-Plasminogen Activator/Urokinase (Catalog # 1310-SE) is measured by its ability to cleave a peptide substrate, N-carbobenzyloxy-Gly-Gly-Arg-7-amido-4-methylcoumarin (Z-GGR-AMC).
Reconstitution Calculator
Background: u-Plasminogen Activator (uPA)/Urokinase
uPA is a serine protease with an extremely limited substrate specificity, cleaving the sequence Cys-Pro-Gly-Arg560-Val561-Val-Gly-Gly-Cys in plasminogen to form plasmin (1). uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium (2). For example, the combination (both low vs. either or both high) of uPA and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), outperforms the single factors as well as other traditional prognostic factors with regard to risk group assessment for breast cancer, particularly in node-negative breast cancer (3). The human uPA is initially synthesized as 431 amino acid precursor with a N-terminal signal peptide (20 residues) (4‑6). The single chain molecule is processed into a disulfide-linked two-chain molecule. The B chain starting at Ile179 corresponds to the catalytic domain. Two forms of the A chain exist, one starting at Ser21 (the long form) and the other at Lys156 (the short form). The resulting two-chain forms have different molecular weights (MW). The B chain is common for both forms whereas the long and short A chains are unique to the high and low MW forms, respectively. The long A chain contains an EGF-like domain, which is responsible for binding of the uPA receptor (uPAR). Both high and low MW forms exist in the purified recombinant human uPA.
- Ellis, V. (2004) in Handbook of Proteolytic Enzymes. Barrett, A.J. et al. eds., Academic Press, San Diego, pp.1677.
- Duffy, M.J. (2002) Biochem. Soc. Trans. 30:207.
- Harbeck, N. et al. (2002) Clin. Breast Cancer 3:196.
- Riccio, A. et al. (1985) Nucleic Acids Res. 13:2785.
- Nagai, M. et al. (1985) Gene 36:183.
- Jacobs, P. et al. (1985) DNA 4:139.
Citations for Recombinant Human u-Plasminogen Activator/Urokinase, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
12
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Dysregulated fibrinolysis and plasmin activation promote the pathogenesis of osteoarthritis
Authors: Wang, Q;Shao, G;Zhao, X;Wong, HH;Chin, K;Zhao, M;Bai, A;Bloom, MS;Love, ZZ;Chu, CR;Cheng, Z;Robinson, WH;
JCI insight
Species: Human hepegivirus
Sample Types: Whole Cells
Applications: Bioassay -
Novel Ex Vivo Zymography Approach for Assessment of Protease Activity in Tissues with Activatable Antibodies
Authors: B Howng, MB Winter, C LePage, I Popova, M Krimm, O Vasiljeva
Pharmaceutics, 2021-09-02;13(9):.
Species: Human
Sample Types: Peptides
Applications: Bioassay -
p53 loss activates prometastatic secretory vesicle biogenesis in the Golgi
Authors: X Tan, P Banerjee, L Shi, GY Xiao, BL Rodriguez, CL Grzeskowia, X Liu, J Yu, DL Gibbons, WK Russell, CJ Creighton, JM Kurie
Science Advances, 2021-06-18;7(25):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1
Authors: T Kryza, T Khan, S Lovell, BS Harrington, J Yin, S Porazinski, M Pajic, H Koistinen, JK Rantala, T Dreyer, V Magdolen, U Reuning, Y He, EW Tate, JD Hooper
Nature Chemical Biology, 2021-04-15;0(0):.
Species: Human
Sample Types: Protein
Applications: Bioassay -
Plasminogen-Dependent Collagenolytic Properties of Staphylococcus aureus in Collagen Gel Cultures of Human Corneal Fibroblasts
Authors: K Sugioka, A Kodama-Tak, T Sato, K Okada, J Murakami, AM Park, H Mishima, Y Shimomura, S Kusaka, T Nishida
Invest. Ophthalmol. Vis. Sci., 2018-10-01;59(12):5098-5107.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Design, Synthesis, and Testing of Potent, Selective Hepsin Inhibitors via Application of an Automated Closed-Loop Optimization Platform.
Authors: Pant S, Mukonoweshuro A, Desai B, Ramjee M, Selway C, Tarver G, Wright A, Birchall K, Chapman T, Tervonen T, Klefstrom J
J Med Chem, 2018-05-14;61(10):4335-4347.
Applications: Enzyme Assay -
Masked Chimeric Antigen Receptor for Tumor-Specific Activation
Authors: X Han, PD Bryson, Y Zhao, GE Cinay, S Li, Y Guo, N Siriwon, P Wang
Mol. Ther, 2017-01-04;25(1):274-284.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Senescent peritoneal mesothelium creates a niche for ovarian cancer metastases
Cell Death Dis, 2016-12-29;7(12):e2565.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode.
Authors: Doni A, Musso T, Morone D, Bastone A, Zambelli V, Sironi M, Castagnoli C, Cambieri I, Stravalaci M, Pasqualini F, Laface I, Valentino S, Tartari S, Ponzetta A, Maina V, Barbieri S, Tremoli E, Catapano A, Norata G, Bottazzi B, Garlanda C, Mantovani A
J Exp Med, 2015-05-11;212(6):905-25.
Species: Mouse
Sample Types: Protein
Applications: Bioassay -
Imaging active urokinase plasminogen activator in prostate cancer.
Authors: Lebeau A, Sevillano N, Markham K, Winter M, Murphy S, Hostetter D, West J, Lowman H, Craik C, VanBrocklin H
Cancer Res, 2015-02-11;75(7):1225-35.
Species: Human
Sample Types: Cell Culture Supernates
Applications: Bioassay -
Gelsolin induces colorectal tumor cell invasion via modulation of the urokinase-type plasminogen activator cascade.
Authors: Zhuo, Jingli, Tan, Ee Hong, Yan, Benedict, Tochhawng, Lalchhan, Jayapal, Manikand, Koh, Shiuan, Tay, Hwee Kee, Maciver, Sutherla, Hooi, Shing Ch, Salto-Tellez, Manuel, Kumar, Alan Pre, Goh, Yaw Chon, Lim, Yaw Chyn, Yap, Celestia
PLoS ONE, 2012-08-21;7(8):e43594.
Applications: ELISA (Standard) -
Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases.
Authors: Endo-Munoz L, Cumming A, Rickwood D, Wilson D, Cueva C, Ng C, Strutton G, Cassady AI, Evdokiou A, Sommerville S, Dickinson I, Guminski A, Saunders NA
Cancer Res., 2010-09-07;70(18):7063-72.
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay
FAQs
-
Has R&D Systems examined the binding ability of 1310-SE to uPAR?
In house, we measured the bioactivity of 1310-SE based on its ability to cleave the Z-GGR-AMC peptide substrate. While we did not measure the binding ability in this assay, we do offer the Recombinant Human uPAR Protein (Catalog # 807-UK), which has been tested in a functional ELISA binding assay with 1310-SE. We have found that the 1310-SE protein is able to bind to uPAR through this testing.
Reviews for Recombinant Human u-Plasminogen Activator/Urokinase, CF
There are currently no reviews for this product. Be the first to review Recombinant Human u-Plasminogen Activator/Urokinase, CF and earn rewards!
Have you used Recombinant Human u-Plasminogen Activator/Urokinase, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image